Outcomes of smokers and drinkers with esophageal cancer after surgery
Long-term Outcomes of Smoker and Drinker With Esophageal Squamous Cell Carcinoma After Esophagectomy
This study looks at how smoking and drinking habits affect the survival of people with esophageal cancer after they have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2957 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Sichuan Cancer Hospital and Research Institute Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06269341 on ClinicalTrials.gov |
What this trial studies
This observational study examines the overall survival outcomes of patients with esophageal squamous cell carcinoma who have undergone esophagectomy, focusing on the impact of smoking and drinking habits. It highlights that patients who abstained from alcohol and tobacco had significantly better survival rates post-surgery. The study also explores the survival differences among those with varying histories of smoking and drinking. No interventions are applied, as the study is observational in nature.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with esophageal squamous cell carcinoma who have undergone esophagectomy.
Not a fit: Patients with non-squamous cell carcinoma or those who have undergone incomplete tumor removal will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the importance of lifestyle choices on survival outcomes for esophageal cancer patients.
How similar studies have performed: Previous studies have indicated that lifestyle factors such as smoking and drinking significantly affect cancer outcomes, suggesting that this approach is supported by existing literature.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients with esophageal cancer Exclusion Criteria: (1) pathology confirmed a non-squamous cell carcinoma, (2) the tumor was located outside of the thoracic region, (3) R1/R2 resection was performed indicating incomplete tumor removal, (4) evidence of distant tumor metastasis was observed, (5) they underwent preoperative neoadjuvant therapy, (6) pTis/T1a stage (7) Missing data.
Where this trial is running
Chengdu, Sichuan
- Sichuan Cancer Hospital and Research Institute — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Lin Peng
- Email: doclinpeng@163.com
- Phone: 8618908178797
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.